Core Viewpoint - The approval of ALMB-0166 for Phase II clinical trials in China represents a significant advancement in the treatment of Parkinson's disease, addressing a critical need for new therapies in this area [1][2]. Group 1: Company Developments - The company has received approval from the National Medical Products Administration of China to conduct Phase II clinical trials for ALMB-0166, a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin43 (Cx43) [1]. - ALMB-0166 is developed by the company's subsidiary, AlaMab Therapeutics Inc., and is intended for treating neurological diseases such as Parkinson's disease, acute ischemic stroke, and acute spinal cord injury [1]. Group 2: Industry Context - Parkinson's disease is the second most common neurodegenerative disease globally, characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies [2]. - Current treatments, primarily based on levodopa, only alleviate symptoms without reversing disease progression or achieving a cure, highlighting the urgent need for new therapeutic options [2]. - ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, thereby maximizing neuroprotection [2]. - Preclinical studies in subacute and chronic Parkinson's disease animal models have shown that ALMB-0166 significantly inhibits the reduction of dopamine levels in the brain and restores behavioral and functional abilities, demonstrating a favorable dose-response relationship [2]. Group 3: Future Plans - The company is committed to advancing the clinical research of ALMB-0166 across various indications, aiming for its expedited market launch [3].
石药集团(01093.HK)：ALMB-0166在中国获临床试验批准用于治疗帕金森氏症